Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Cash from Investing Activities (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Cash from Investing Activities for 11 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Investing Activities rose 113.25% year-over-year to $2.0 million, compared with a TTM value of $8.0 million through Sep 2025, up 828.04%, and an annual FY2024 reading of $514529.0, down 84.18% over the prior year.
  • Cash from Investing Activities was $2.0 million for Q3 2025 at BioRestorative Therapies, down from $2.1 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $3.0 million in Q2 2024 and bottomed at -$9.9 million in Q3 2022.
  • Average Cash from Investing Activities over 4 years is -$209099.1, with a median of $819030.0 recorded in 2023.
  • Peak annual rise in Cash from Investing Activities hit 4485.96% in 2024, while the deepest fall reached 294.08% in 2024.
  • Year by year, Cash from Investing Activities stood at -$3.2 million in 2022, then surged by 97.39% to -$84798.0 in 2023, then skyrocketed by 1907.36% to $1.5 million in 2024, then skyrocketed by 30.34% to $2.0 million in 2025.
  • Business Quant data shows Cash from Investing Activities for BRTX at $2.0 million in Q3 2025, $2.1 million in Q2 2025, and $2.4 million in Q1 2025.